Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

5 results
Display

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer

Lim JU, Woo IS, Jung YH, Byeon JH, Park CK, Kim TJ, Kim HR

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Post-Progression Survival in Patients with Non-Small Cell Lung Cancer with Clinically Acquired Resistance to Gefitinib

Kim H, Yun T, Lee YJ, Han JY, Kim HT, Lee GK

Most patients with tyrosine kinase inhibitor (TKI)-sensitive non-small cell lung cancer (NSCLC) eventually develop acquired resistance to TKIs. Factors that affect TKI-sensitive patient survival after progression during TKI treatment remain...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure

Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS

BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib

Kwon T, Rho JK, Lee JC, Park YH, Shin HJ, Cho S, Kang YK, Kim BY, Yoon DY, Yu DY

Redox adaptation is an important concept that explains the mechanisms by which cancer cells survive under persistent endogenous oxidative stress and become resistant to certain anticancer agents. To investigate this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation

Hur GY, Lee SY, Lee SH, Kim SJ, Lee KJ, Jung JY, Lee EJ, Kang EH, Jung KH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH

  • KMID: 1047088
  • Exp Mol Med.
  • 2007 Jun;39(3):367-375.
The EGFR plays an essential role in goblet cell hyperplasia and mucus hypersecretion. EGFR has an intrinsic tyrosine kinase activity that, when activated, induces the production of MUC5AC through the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr